Review
MDR1 Genotype-related Pharmacokinetics: Fact or Fiction?

https://doi.org/10.2133/dmpk.20.391Get rights and content

Summary:

Multidrug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette superfamily of membrane transporters. A number of various types of structurally unrelated drugs are substrates for MDR1, and MDR1 and other transporters are recognized as an important class of proteins for regulating pharmacokinetics. The first investigation of the effects of MDR1 genotypes on pharmacotherapy was reported in 2000; a silent single nucleotide polymorphism (SNP), C3435T in exon 26, was found to be associated with the duodenal expression of MDR1, and thereby the plasma concentration of digoxin after oral administration. In the last 5 years, clinical studies have been conducted around the world on the association of MDR1 genotype with MDR1 expression and function in tissues, and with the pharmacokinetics and pharmacodynamics of drugs; however, there are still discrepancies in the results on C3435T. In 1995, a novel concept to predict in vivo oral pharmacokinetic performance from data on in vivo permeability and in vitro solubility has been proposed, and this Biopharmaceutical Classification System strongly suggested that the effects of intestinal MDR1 on the intestinal absorption of substrates is minimal in the case of commercially available oral drugs, and therefore MDR1 genotypes are little associated with the pharmacokinetics after oral administration. This review summarizes the latest reports for the future individualization of pharmacotherapy based on MDR1 genotyping, and attempts to explain discrepancies.

References (251)

  • E. Schaeffeler et al.

    Frequency of C3435T polymorphism of MDR1 gene in African people

    Lancet

    (2001)
  • H. Zheng et al.

    The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients

    Hum. Immunol.

    (2002)
  • T. Nakamura et al.

    Simultaneous determination of single nucleotide polymorphisms of MDR1 genes by electrochemical DNA chip

    Drug Metab. Pharmacokinet.

    (2005)
  • N. Morita et al.

    Human MDR1 polymorphism: G2677T A and C3435T have no effect on MDR1 transport activities

    Biochem. Pharmacol.

    (2003)
  • M.M. Cornwell et al.

    SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity

    J. Biol. Chem.

    (1993)
  • T. Ohga et al.

    Direct involvement of the Y-box binding protein YB-1 in genotoxic stress- induced activation of the human multidrug resistance 1 gene

    J. Biol. Chem.

    (1998)
  • K. Koike et al.

    Nuclear translocation of the Y-box binding protein by ultraviolet irradiation

    FEBS Lett.

    (1997)
  • M.E. Goldsmith et al.

    A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene

    J. Biol. Chem.

    (1993)
  • N.J. Combates et al.

    NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter

    J. Biol. Chem.

    (1994)
  • G. Zhou et al.

    NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells

    J. Biol. Chem.

    (1997)
  • D.P. Guimaraes et al.

    TP53: a key gene in human cancer

    Biochimie

    (2002)
  • P. Friedlander et al.

    Regulation of mutant p53 temperature-sensitive DNA binding

    J. Biol. Chem.

    (1996)
  • C. Cadwell et al.

    The effects of wild- type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

    Gene

    (2001)
  • J. Sampath et al.

    Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1

    J. Biol. Chem.

    (2001)
  • I.B. Roninson et al.

    Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells

    Proc. Natl. Acad. Sci. USA

    (1986)
  • T. Sakaeda et al.

    MDR1 genotype-related pharmacokinetics and pharmacodynamics

    Biol. Pharm. Bull.

    (2002)
  • T. Sakaeda et al.

    Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs

    Pharmacogenomics

    (2003)
  • T. Sakaeda et al.

    Pharmacogenetics of drug transporters and its impact on the pharmacotherapy

    Curr. Top. Med. Chem.

    (2004)
  • N. Okamura et al.

    Pharmacogenomics of MDR and MRP subfamilies

    Personalized Med.

    (2004)
  • I. Ieiri et al.

    The MDR1 (ABCB1) gene polymorphism and its clinical implications

    Clin. Pharmacokinet.

    (2004)
  • M. Schwab et al.

    Genetic polymorphisms of the human MDR1 drug transporter

    Annu. Rev. Pharmacol. Toxicol.

    (2003)
  • C. Marzolini et al.

    Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

    Clin. Pharmacol. Ther.

    (2004)
  • M. Eichelbaum et al.

    Clinical aspects of the MDR1 (ABCB1) gene polymorphism

    Ther. Drug Monit.

    (2004)
  • E.L. Woodahl et al.

    The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function

    Curr. Drug Metab.

    (2004)
  • T. Nakamura

    MDR1 genotypes related to pharmacokinetics and MDR1 expression

    Yakugaku Zasshi

    (2003)
  • C. Pauli-Magnus et al.

    Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)

    Pharm. Res.

    (2004)
  • F. Thiebaut et al.

    Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

    Proc. Natl. Acad. Sci. USA

    (1987)
  • Y. Tanigawara et al.

    Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC- PK1)

    J. Pharmacol. Exp. Ther.

    (1992)
  • N. Okamura et al.

    Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney

    J. Pharmacol. Exp. Ther.

    (1993)
  • T. Sakaeda et al.

    Simvastatin and lovastatin, but not pravastatin, interact with MDR1

    J. Pharm. Pharmacol.

    (2002)
  • M. Kakumoto et al.

    MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs

    Biol. Pharm. Bull.

    (2002)
  • S.C. Hyde et al.

    Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport

    Nature

    (1990)
  • M. Dean et al.

    The human ATP-binding cassette (ABC) transporter superfamily

    Genome Res.

    (2001)
  • S. Hoffmeyer et al.

    Functional polymorphisms of the human multidrug- resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

    Proc. Natl. Acad. Sci. USA

    (2000)
  • D.F. Callen et al.

    Localization of the human multiple drug resistance gene, MDR1, to 7q21.1

    Hum. Genet.

    (1987)
  • J.E. Chin et al.

    Structure and expression of the human MDR1 (P-glycoprotein) gene family

    Mol. Cell Biol.

    (1989)
  • S. Ito et al.

    Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects

    Pharmacogenetics

    (2001)
  • I. Cascorbi et al.

    Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects

    Clin. Pharmacol. Ther.

    (2001)
  • M. Tanabe et al.

    Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene

    J. Pharmacol. Exp. Ther.

    (2001)
  • R.B. Kim et al.

    Identification of functionally variant MDR1 alleles among European Americans and African Americans

    Clin. Pharmacol. Ther.

    (2001)

    • Cited by (144)

    • The association of a genetic variant in multi-drug resistance gene and colorectal cancer susceptibility

      2021, Gene Reports

    • Drug Transporter Function-Implications in CKD

      2016, Advances in Chronic Kidney Disease

    • MDR1 rs1045642 Variant Is Linked with Lower Expression and Extends Overall Survival of Multiple Myeloma: A Hospital-Based Case-Control Study

      2023, Russian Journal of Genetics

    • Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject

      2022, Translational and Clinical Pharmacology

    • Investigation of Relation Between MDR1 Gene and Ankylosing Spondylitis: Case Control Research

      2022, Turkiye Klinikleri Journal of Medical Sciences

    • P-glycoprotein polymorphism: Genetic and epigenetic changes

      2021, An Introduction to P-Glycoprotein
    View all citing articles on Scopus
    View full text
    Copyright © 2005 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.